For drugs like Stelara (ustekinumab, Johnson & Johnson), which faced biosimilar entry beginning in 2023 in the U.S., and Eylea (aflibercept, Regeneron), where biosimilar entry occurred in 2024, the Humira retention data provides a more accurate revenue tail model than historical small molecule LOE curves
The reaction was started with addition of an equal volume of DTNB (6 mM) and NADPH (100 M) and the increase in A 412 during the first 3 min was recorded
I certainly do
Symptoms of severe hypoglycemia include sudden shakiness, profuse sweating, intense anxiety, rapid or irregular heartbeat, and difficulty speaking
Yes, its currently opt-in, but as a first step, this moves millions of patients from no access to some access
16 Healthcare shifts and potential savings GLP-1 medications arent just shaking up food habits theyre also transforming the healthcare landscape